• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

    11/6/24 5:08:07 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTOR alert in real time by email
    SC 13G/A 1 ctor_13ga.htm CTOR 13G/A

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Citius Oncology, Inc.

    (formerly known as TenX Keane Acquisition)

    (Name of Issuer)
     

    Ordinary Shares, $0.0001 par value

    (Title of Class of Securities)
     

    17331Y109

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Hudson Bay Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Sander Gerber

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     
     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Citius Oncology, Inc. (f/k/a TenX Keane Acquisition), a Cayman Islands company (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by Hudson Bay Capital Management LP (the “Investment Manager”) and Mr. Sander Gerber (“Mr. Gerber”), who are collectively referred to herein as “Reporting Persons.”

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 28 Havemeyer Place, 2nd Floor, Greenwich, CT 06830.

     

    Item 2(c). CITIZENSHIP:
       
      The Investment Manager is a Delaware limited partnership.  Mr. Gerber is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Ordinary Shares, $0.0001 par value (the “Ordinary Shares”).

     

    Item 2(e). CUSIP NUMBER:
       
      17331Y109

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ý Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

     
     

     

      (g) ý

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The Investment Manager serves as the investment manager to HB Strategies LLC, in whose name the securities reported herein were held. As such, the Investment Manager may have been deemed to be the beneficial owner of all securities held by HB Strategies LLC. Mr. Gerber serves as the managing member of Hudson Bay Capital GP LLC, which is the general partner of the Investment Manager.  Mr. Gerber disclaims beneficial ownership of these securities.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.
     
     

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 6, 2024

     

    HUDSON BAY CAPITAL MANAGEMENT LP    
         
         
    By: /s/ Sander Gerber    
    Name: Sander Gerber    
    Title: Authorized Signatory    
         
         
    /s/ Sander Gerber    
    SANDER GERBER    

     

    Get the next $CTOR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTOR

    DatePrice TargetRatingAnalyst
    11/27/2024$3.00Buy
    Maxim Group
    More analyst ratings

    $CTOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

    LYMPHIR commercial availability planned for the fourth quarter of 2025 $12.5 million in gross financings raised during the quarter by Citius Pharmaceuticals, with an additional $9 million raised by Citius Oncology in July 2025, to facilitate LYMPHIR pre-launch initiatives and drive successful market introduction CRANFORD, N.J., Aug. 12, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal third quarter ended June 30, 2025.

    8/12/25 4:30:00 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators

    NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /PRNewswire/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for years. There are more than 30 million Americans who have a rare disease, so there is a growing need for accurate diagnoses and eff

    8/6/25 8:30:00 AM ET
    $AMGN
    $CTOR
    $FOLD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Citius Oncology Announces Closing of $9.0 Million Public Offering

    CRANFORD, N.J., July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), today announced the closing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The warrants have an exercise price of $1.32 per share, are immediately exercisable upon issuance, and expire five years from the date of issuance. Gross proceeds from the offering, before deducting placement agent fees and other estimated offering expenses, are approximately $9.0

    7/17/25 4:30:00 PM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTOR
    SEC Filings

    View All

    Citius Oncology Inc. filed SEC Form 8-K: Other Events

    8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

    8/18/25 5:26:25 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Citius Oncology Inc.

    424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

    8/18/25 5:25:16 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citius Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

    8/12/25 4:45:56 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Citius Oncology with a new price target

    Maxim Group initiated coverage of Citius Oncology with a rating of Buy and set a new price target of $3.00

    11/27/24 8:17:22 AM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mayersohn Joel David acquired 21,228 shares (SEC Form 4)

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    8/7/25 5:02:07 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mayersohn Joel David

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    12/16/24 5:05:14 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Holuka Eugene Myron

    4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

    12/16/24 4:09:27 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTOR
    Financials

    Live finance-specific insights

    View All

    Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

    Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

    12/27/24 5:00:00 PM ET
    $CTOR
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTOR
    Leadership Updates

    Live Leadership Updates

    View All

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

    6/26/25 11:44:00 AM ET
    $ADCT
    $CTOR
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CTOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

    SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

    11/6/24 5:08:07 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

    SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

    9/5/24 9:23:54 AM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Citius Oncology Inc.

    SC 13D - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

    8/16/24 4:34:29 PM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care